diaendoСахарный диабетDiabetes mellitus2072-03512072-0378Endocrinology research centre10.14341/DM10130diaendo-10130Research ArticleОбзорыReviewФакторы роста в терапии язвенных дефектов при синдроме диабетической стопыGrowth factors in the treatment of diabetic foot syndromehttps://orcid.org/0000-0003-0798-0139КомелягинаЕлена ЮрьевнаKomelyaginaElena Y.

кандидат медицинских наук, заведующая отделением диабетической стопы

MD, PhD

komelelena@yandex.ruhttps://orcid.org/0000-0002-9944-2997АнциферовМихаил БорисовичAntsiferovMichail B.

д.м.н., профессор

MD, PhD, Professor

antsiferov@rambler.ruЭндокринологический диспансер Департамента здравоохранения города Москвы; Российская медицинская академия непрерывного последипломного образованияРоссияEndocrinology department of the Moscow Health Department; Russian Medical Academy of Continuing Medical EducationRussian Federation201925102019224377383Copyright © Комелягина Е.Ю., Анциферов М.Б., 20192019Комелягина Е.Ю., Анциферов М.Б.Komelyagina E.Y., Antsiferov M.B.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.dia-endojournals.ru/jour/article/view/10130

Факторы роста играют одну из ключевых ролей в процессе заживления ран. Их дефицит приводит к хронизации процесса и длительным срокам заживления раневых дефектов. В этой связи в терапии хронических ран, включая язвенные дефекты при синдроме диабетической стопы, применяются различные факторы роста. Целью настоящего обзора явился анализ данных литературы по эффективности применения эпидермального фактора роста, плазмы, обогащенной тромбоцитами, тромбоцитарного фактора роста у пациентов с синдромом диабетической стопы. Анализировалось влияние терапии указанными факторами роста на заживление язвенных дефектов и его сроки. Данные опубликованных работ демонстрируют положительное влияние различных факторов роста на течение процесса заживления язвенных дефектов при синдроме диабетической стопы. Однако уровень доказательной базы большинства исследований невысок. В этой связи в настоящее время нет возможности сделать заключение о преимуществе терапии факторами роста. Необходимы дальнейшие исследования эффективности лечения факторами роста язвенных дефектов при синдроме диабетической стопы с высоким уровнем доказательности для обоснования их применения в рутинной клинической практике.

Growth factors play a key role in wound healing, deficiency of which leads to delayed healing. Various growth factors are used in the treatment of chronic wounds, including diabetic foot ulcers. The purpose of this review was to analyse the literature data on the effectiveness of epidermal growth factor, platelet-rich plasma and platelet growth factor in patients with diabetic foot syndrome. The effect of treatment with these growth factors on healing of diabetic foot ulcers and healing time were analysed. Published studies, mostly with low level of evidence, demonstrate a positive effect of various growth factors on the healing process of diabetic foot ulcers. Currently, there is no conclusion on the advantages of growth factor therapy. Further studies with a high level of evidence are needed to justify their use in routine clinical practice.

сахарный диабетсиндром диабетической стопыфакторы ростаэпидермальный фактор ростаплазмаобогащенная тромбоцитамитромбоцитарный фактор ростаdiabetes mellitusdiabetic foot syndromegrowth factorsepidermal growth factorplatelet-rich plasmaplatelet growth factorReferencesZhang J. Growth factors in the pathogenesis of diabetic foot ulcers. Front Biosci. 2018;23(1):310-317. doi: https://doi.org/10.2741/4593Zhang J. Growth factors in the pathogenesis of diabetic foot ulcers. Front Biosci. 2018;23(1):310-317. doi: https://doi.org/10.2741/4593Park JW, Hwang SR, Yoon IS. Advanced Growth Factor Delivery Systems in Wound Management and Skin Regeneration. Molecules. 2017;22(8). doi: https://doi.org/10.3390/molecules22081259Park JW, Hwang SR, Yoon IS. Advanced Growth Factor Delivery Systems in Wound Management and Skin Regeneration. Molecules. 2017;22(8). doi: https://doi.org/10.3390/molecules22081259Patel S, Srivastava S, Singh MR, Singh D. Mechanistic insight into diabetic wounds: Pathogenesis, molecular targets and treatment strategies to pace wound healing. Biomed Pharmacother. 2019;112:108615. doi: https://doi.org/10.1016/j.biopha.2019.108615Patel S, Srivastava S, Singh MR, Singh D. Mechanistic insight into diabetic wounds: Pathogenesis, molecular targets and treatment strategies to pace wound healing. Biomed Pharmacother. 2019;112:108615. doi: https://doi.org/10.1016/j.biopha.2019.108615Steed DL. Role of Growth Factors in the Treatment of Diabetic Foot Ulceration. In: Veves A, Giurini J, LoGerfo F, editors. The Diabetic Foot. 2nd ed. Totowa: Humana Press; 2006. p. 447-458.Steed DL. Role of Growth Factors in the Treatment of Diabetic Foot Ulceration. In: Veves A, Giurini J, LoGerfo F, editors. The Diabetic Foot. 2nd ed. Totowa: Humana Press; 2006. p. 447-458.Qing C. The molecular biology in wound healing & non-healing wound. Chin J Traumatol. 2017;20(4):189-193. doi: https://doi.org/10.1016/j.cjtee.2017.06.001Qing C. The molecular biology in wound healing & non-healing wound. Chin J Traumatol. 2017;20(4):189-193. doi: https://doi.org/10.1016/j.cjtee.2017.06.001Bruhn-Olszewska B, Korzon-Burakowska A, Gabig-Ciminska M, et al. Molecular factors involved in the development of diabetic foot syndrome. Acta Biochim Pol. 2012;59(4):507-513.Bruhn-Olszewska B, Korzon-Burakowska A, Gabig-Ciminska M, et al. Molecular factors involved in the development of diabetic foot syndrome. Acta Biochim Pol. 2012;59(4):507-513.Moustakas A, Heldin P. TGFβ and matrix-regulated epithelial to mesenchymal transition. Biochim Biophys Acta Gen Subj. 2014;1840(8):2621-2634. doi: https://doi.org/10.1016/j.bbagen.2014.02.004Moustakas A, Heldin P. TGFβ and matrix-regulated epithelial to mesenchymal transition. Biochim Biophys Acta Gen Subj. 2014;1840(8):2621-2634. doi: https://doi.org/10.1016/j.bbagen.2014.02.004Yan C, Grimm WA, Garner WL, et al. Epithelial to Mesenchymal Transition in Human Skin Wound Healing Is Induced by Tumor Necrosis Factor-α through Bone Morphogenic Protein-2. Am J Pathol. 2010;176(5):2247-2258. doi: https://doi.org/10.2353/ajpath.2010.090048Yan C, Grimm WA, Garner WL, et al. Epithelial to Mesenchymal Transition in Human Skin Wound Healing Is Induced by Tumor Necrosis Factor-α through Bone Morphogenic Protein-2. Am J Pathol. 2010;176(5):2247-2258. doi: https://doi.org/10.2353/ajpath.2010.090048Yoshida M, Okubo N, Chosa N, et al. TGF-beta-operated growth inhibition and translineage commitment into smooth muscle cells of periodontal ligament-derived endothelial progenitor cells through Smad- and p38 MAPK-dependent signals. Int J Biol Sci. 2012;8(7):1062-1074. doi: https://doi.org/10.7150/ijbs.4488Yoshida M, Okubo N, Chosa N, et al. TGF-beta-operated growth inhibition and translineage commitment into smooth muscle cells of periodontal ligament-derived endothelial progenitor cells through Smad- and p38 MAPK-dependent signals. Int J Biol Sci. 2012;8(7):1062-1074. doi: https://doi.org/10.7150/ijbs.4488Профилактика и лечение заболеваний стопы при диабете. Руководство, документы и рекомендации. Полная русскоязычная версия. 2016. [International Consensus on the Diabetic Foot. Russian version. 2016. (In Russ.)]Профилактика и лечение заболеваний стопы при диабете. Руководство, документы и рекомендации. Полная русскоязычная версия. 2016. [International Consensus on the Diabetic Foot. Russian version. 2016. (In Russ.)]Cohen S. Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new-born animal. J Biol Chem. 1962;237:1555-1562.Cohen S. Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new-born animal. J Biol Chem. 1962;237:1555-1562.Nanney LB. Epidermal and Dermal Effects of Epidermal Growth Factor During Wound Repair. J Invest Dermatol. 1990;94(5):624-629. doi: https://doi.org/10.1111/1523-1747.ep12876204Nanney LB. Epidermal and Dermal Effects of Epidermal Growth Factor During Wound Repair. J Invest Dermatol. 1990;94(5):624-629. doi: https://doi.org/10.1111/1523-1747.ep12876204Tiaka EK, Papanas N, Manolakis AC, Georgiadis GS. Epidermal growth factor in the treatment of diabetic foot ulcers: an update. Perspect Vasc Surg Endovasc Ther. 2012;24(1):37-44. doi: https://doi.org/10.1177/1531003512442093Tiaka EK, Papanas N, Manolakis AC, Georgiadis GS. Epidermal growth factor in the treatment of diabetic foot ulcers: an update. Perspect Vasc Surg Endovasc Ther. 2012;24(1):37-44. doi: https://doi.org/10.1177/1531003512442093Barrientos S, Stojadinovic O, Golinko MS, et al. Growth factors and cytokines in wound healing. Wound Repair Regen. 2008;16(5):585-601. doi: https://doi.org/10.1111/j.1524-475X.2008.00410.xBarrientos S, Stojadinovic O, Golinko MS, et al. Growth factors and cytokines in wound healing. Wound Repair Regen. 2008;16(5):585-601. doi: https://doi.org/10.1111/j.1524-475X.2008.00410.xAcosta JB, Savigne W, Valdez C, et al. Epidermal growth factor intralesional infiltrations can prevent amputation in patients with advanced diabetic foot wounds. Int Wound J. 2006;3(3):232-239. doi: https://doi.org/10.1111/j.1742-481X.2006.00237.xAcosta JB, Savigne W, Valdez C, et al. Epidermal growth factor intralesional infiltrations can prevent amputation in patients with advanced diabetic foot wounds. Int Wound J. 2006;3(3):232-239. doi: https://doi.org/10.1111/j.1742-481X.2006.00237.xBrown GL, Nanney LB, Griffen J, et al. Enhancement of Wound Healing by Topical Treatment with Epidermal Growth Factor. New Eng J Med. 1989;321(2):76-79. doi: https://doi.org/10.1056/nejm198907133210203Brown GL, Nanney LB, Griffen J, et al. Enhancement of Wound Healing by Topical Treatment with Epidermal Growth Factor. New Eng J Med. 1989;321(2):76-79. doi: https://doi.org/10.1056/nejm198907133210203Tsang MW, Wong WKR, Hung CS, et al. Human Epidermal Growth Factor Enhances Healing of Diabetic Foot Ulcers. Diabetes Care. 2003;26(6):1856-1861. doi: https://doi.org/10.2337/diacare.26.6.1856Tsang MW, Wong WKR, Hung CS, et al. Human Epidermal Growth Factor Enhances Healing of Diabetic Foot Ulcers. Diabetes Care. 2003;26(6):1856-1861. doi: https://doi.org/10.2337/diacare.26.6.1856Hong JP, Jung HD, Kim YW. Recombinant Human Epidermal Growth Factor (EGF) to Enhance Healing for Diabetic Foot Ulcers. Ann Plast Surg. 2006;56(4):394-398. doi: https://doi.org/10.1097/01.sap.0000198731.12407.0cHong JP, Jung HD, Kim YW. Recombinant Human Epidermal Growth Factor (EGF) to Enhance Healing for Diabetic Foot Ulcers. Ann Plast Surg. 2006;56(4):394-398. doi: https://doi.org/10.1097/01.sap.0000198731.12407.0cViswanathan V, Pendsey S. A phase III study to evaluate the safety and efficacy of recombinant human epidermal growth factor (REGEN-D TM 150) in healing diabetic foot ulcers. Wounds. 2006;18:186-196.Viswanathan V, Pendsey S. A phase III study to evaluate the safety and efficacy of recombinant human epidermal growth factor (REGEN-D TM 150) in healing diabetic foot ulcers. Wounds. 2006;18:186-196.Fernández-Montequín JI, Infante-Cristiá E, Valenzuela-Silva C, et al. Intralesional injections of Citoprot-P®(recombinant human epidermal growth factor) in advanced diabetic foot ulcers with risk of amputation. Int Wound J. 2007;4(4):333-343. doi: https://doi.org/10.1111/j.1742-481X.2007.00344.xFernández-Montequín JI, Infante-Cristiá E, Valenzuela-Silva C, et al. Intralesional injections of Citoprot-P®(recombinant human epidermal growth factor) in advanced diabetic foot ulcers with risk of amputation. Int Wound J. 2007;4(4):333-343. doi: https://doi.org/10.1111/j.1742-481X.2007.00344.xTuyet HL, Nguyen Quynh TT, Vo Hoang Minh H, et al. The efficacy and safety of epidermal growth factor in treatment of diabetic foot ulcers: the preliminary results. Int Wound J. 2009;6(2):159-166. doi: https://doi.org/10.1111/j.1742-481X.2009.00594.xTuyet HL, Nguyen Quynh TT, Vo Hoang Minh H, et al. The efficacy and safety of epidermal growth factor in treatment of diabetic foot ulcers: the preliminary results. Int Wound J. 2009;6(2):159-166. doi: https://doi.org/10.1111/j.1742-481X.2009.00594.xFernandez-Montequin JI, Valenzuela-Silva CM, Diaz OG, et al. Intra-lesional injections of recombinant human epidermal growth factor promote granulation and healing in advanced diabetic foot ulcers: multicenter, randomised, placebo-controlled, double-blind study. Int Wound J. 2009;6(6):432-443. doi: https://doi.org/10.1111/j.1742-481X.2009.00641.xFernandez-Montequin JI, Valenzuela-Silva CM, Diaz OG, et al. Intra-lesional injections of recombinant human epidermal growth factor promote granulation and healing in advanced diabetic foot ulcers: multicenter, randomised, placebo-controlled, double-blind study. Int Wound J. 2009;6(6):432-443. doi: https://doi.org/10.1111/j.1742-481X.2009.00641.xFernández-Montequín JI, Betancourt BY, Leyva-Gonzalez G, et al. Intralesional administration of epidermal growth factor-based formulation (Heberprot-P) in chronic diabetic foot ulcer: treatment up to complete wound closure. Int Wound J. 2009;6(1):67-72. doi: https://doi.org/10.1111/j.1742-481X.2008.00561.xFernández-Montequín JI, Betancourt BY, Leyva-Gonzalez G, et al. Intralesional administration of epidermal growth factor-based formulation (Heberprot-P) in chronic diabetic foot ulcer: treatment up to complete wound closure. Int Wound J. 2009;6(1):67-72. doi: https://doi.org/10.1111/j.1742-481X.2008.00561.xGomez-Villa R, Aguilar-Rebolledo F, Lozano-Platonoff A, et al. Efficacy of intralesional recombinant human epidermal growth factor in diabetic foot ulcers in Mexican patients: A randomized double-blinded controlled trial. Wound Repair Regen. 2014;22(4):497-503. doi: https://doi.org/10.1111/wrr.12187Gomez-Villa R, Aguilar-Rebolledo F, Lozano-Platonoff A, et al. Efficacy of intralesional recombinant human epidermal growth factor in diabetic foot ulcers in Mexican patients: A randomized double-blinded controlled trial. Wound Repair Regen. 2014;22(4):497-503. doi: https://doi.org/10.1111/wrr.12187Henning PR, Grear BJ. Platelet-rich plasma in the foot and ankle. Curr Rev Musculoskelet Med. 2018;11(4):616-623. doi: https://doi.org/10.1007/s12178-018-9522-zHenning PR, Grear BJ. Platelet-rich plasma in the foot and ankle. Curr Rev Musculoskelet Med. 2018;11(4):616-623. doi: https://doi.org/10.1007/s12178-018-9522-zMcCarrel TM, Minas T, Fortier LA. Optimization of Leukocyte Concentration in Platelet-Rich Plasma for the Treatment of Tendinopathy. J Bone Joint Surg. 2012;94(19):e143. doi: https://doi.org/10.2106/jbjs.l.00019McCarrel TM, Minas T, Fortier LA. Optimization of Leukocyte Concentration in Platelet-Rich Plasma for the Treatment of Tendinopathy. J Bone Joint Surg. 2012;94(19):e143. doi: https://doi.org/10.2106/jbjs.l.00019Knighton DR, Ciresi K, Fiegel VD, et al. Stimulation of repair in chronic, nonhealing, cutaneous ulcers using platelet-derived wound healing formula. Surg Gynecol Obstet. 1990;170(1):56-60.Knighton DR, Ciresi K, Fiegel VD, et al. Stimulation of repair in chronic, nonhealing, cutaneous ulcers using platelet-derived wound healing formula. Surg Gynecol Obstet. 1990;170(1):56-60.Steed DL, Golsten B, Hambley R, et al. Clinical trials with purified platelet realisate. In: Barbul A, Liss A, editors. Clinical and Experimental Approaches to Dermal and Epidermal Repair: Normal and Chronic Wounds. New York; 1990. p. 103-113.Steed DL, Golsten B, Hambley R, et al. Clinical trials with purified platelet realisate. In: Barbul A, Liss A, editors. Clinical and Experimental Approaches to Dermal and Epidermal Repair: Normal and Chronic Wounds. New York; 1990. p. 103-113.Knighton DR, Ciresi KF, Fiegel VD, et al. Classification and treatment of chronic nonhealing wounds. Successful treatment with autologous platelet-derived wound healing factors (PDWHF). Ann Surg. 1986;204(3):322-330. doi: https://doi.org/10.1097/00000658-198609000-00011Knighton DR, Ciresi KF, Fiegel VD, et al. Classification and treatment of chronic nonhealing wounds. Successful treatment with autologous platelet-derived wound healing factors (PDWHF). Ann Surg. 1986;204(3):322-330. doi: https://doi.org/10.1097/00000658-198609000-00011Atri SC, Misra J, Bisht D, Misra K. Use of homologous platelet factors in achieving total healing of recalcitrant skin ulcers. Surgery. 1990;108(3):508-512.Atri SC, Misra J, Bisht D, Misra K. Use of homologous platelet factors in achieving total healing of recalcitrant skin ulcers. Surgery. 1990;108(3):508-512.Hirase T, Ruff E, Surani S, Ratnani I. Topical application of platelet-rich plasma for diabetic foot ulcers: A systematic review. World J Diabetes. 2018;9(10):172-179. doi: https://doi.org/10.4239/wjd.v9.i10.172Hirase T, Ruff E, Surani S, Ratnani I. Topical application of platelet-rich plasma for diabetic foot ulcers: A systematic review. World J Diabetes. 2018;9(10):172-179. doi: https://doi.org/10.4239/wjd.v9.i10.172Просянникова Н.В. Аутологичная, богатая тромбоцитами плазма, в лечении язвенных поражений кожи нижних конечностей: Дис. … канд. мед. наук. — М.; 2014. [Prosyannikova NV. Autologichnaya, bogataya trombotsitami plazma, v lechenii yazvennykh porazheniy kozhi nizhnikh konechnostey. [dissertation] Moscow; 2014. (In Russ.)]Просянникова Н.В. Аутологичная, богатая тромбоцитами плазма, в лечении язвенных поражений кожи нижних конечностей: Дис. … канд. мед. наук. — М.; 2014. [Prosyannikova NV. Autologichnaya, bogataya trombotsitami plazma, v lechenii yazvennykh porazheniy kozhi nizhnikh konechnostey. [dissertation] Moscow; 2014. (In Russ.)]Халимов Э.В., Михайлов А.Ю., Иванова Л.М. Тромбоцитарный концентрат в комплексном лечении язвенных дефектов при синдроме диабетической стопы. В кн.: Труды Ижевской государственной медицинской академии. Т. 56. — Ижевск; 2018. — С. 57-58. [Trudy Izhevskoy gosudarstvennoy meditsinskoy akademii. Vol. 56. Izhevsk; 2018. p. 57-58. (In Russ.)]Халимов Э.В., Михайлов А.Ю., Иванова Л.М. Тромбоцитарный концентрат в комплексном лечении язвенных дефектов при синдроме диабетической стопы. В кн.: Труды Ижевской государственной медицинской академии. Т. 56. — Ижевск; 2018. — С. 57-58. [Trudy Izhevskoy gosudarstvennoy meditsinskoy akademii. Vol. 56. Izhevsk; 2018. p. 57-58. (In Russ.)]Obolenskiy VN, Ermolova DA, Laberko LA. Clinical and economic effectiveness of the use of platelet-rich plasma in the treatment of chronic wounds. Wound Medicine. 2017;19:27-32. doi: https://doi.org/10.1016/j.wndm.2017.09.001Obolenskiy VN, Ermolova DA, Laberko LA. Clinical and economic effectiveness of the use of platelet-rich plasma in the treatment of chronic wounds. Wound Medicine. 2017;19:27-32. doi: https://doi.org/10.1016/j.wndm.2017.09.001Serra R, Buffone G, Dominijanni A, et al. Application of platelet-rich gel to enhance healing of transmetatarsal amputations in diabetic dysvascular patients. Int Wound J. 2013;10(5):612-615. doi: https://doi.org/10.1111/iwj.12052Serra R, Buffone G, Dominijanni A, et al. Application of platelet-rich gel to enhance healing of transmetatarsal amputations in diabetic dysvascular patients. Int Wound J. 2013;10(5):612-615. doi: https://doi.org/10.1111/iwj.12052Kontopodis N, Tavlas E, Papadopoulos G, et al. Effectiveness of Platelet-Rich Plasma to Enhance Healing of Diabetic Foot Ulcers in Patients With Concomitant Peripheral Arterial Disease and Critical Limb Ischemia. Int J Low Extrem Wounds. 2016;15(1):45-51. doi: https://doi.org/10.1177/1534734615575829Kontopodis N, Tavlas E, Papadopoulos G, et al. Effectiveness of Platelet-Rich Plasma to Enhance Healing of Diabetic Foot Ulcers in Patients With Concomitant Peripheral Arterial Disease and Critical Limb Ischemia. Int J Low Extrem Wounds. 2016;15(1):45-51. doi: https://doi.org/10.1177/1534734615575829Jeong SH, Han SK, Kim WK. Treatment of diabetic foot ulcers using a blood bank platelet concentrate. Plast Reconstr Surg. 2010;125(3):944-952. doi: https://doi.org/10.1097/PRS.0b013e3181cb6589Jeong SH, Han SK, Kim WK. Treatment of diabetic foot ulcers using a blood bank platelet concentrate. Plast Reconstr Surg. 2010;125(3):944-952. doi: https://doi.org/10.1097/PRS.0b013e3181cb6589Game F, Jeffcoate W, Tarnow L, et al. LeucoPatch system for the management of hard-to-heal diabetic foot ulcers in the UK, Denmark, and Sweden: an observer-masked, randomised controlled trial. Lancet Diabetes Endocrinol. 2018;6(11):870-878. doi: https://doi.org/10.1016/s2213-8587(18)30240-7Game F, Jeffcoate W, Tarnow L, et al. LeucoPatch system for the management of hard-to-heal diabetic foot ulcers in the UK, Denmark, and Sweden: an observer-masked, randomised controlled trial. Lancet Diabetes Endocrinol. 2018;6(11):870-878. doi: https://doi.org/10.1016/s2213-8587(18)30240-7Eldor R, Raz I, Ben Yehuda A, Boulton AJ. New and experimental approaches to treatment of diabetic foot ulcers: a comprehensive review of emerging treatment strategies. Diabet Med. 2004;21(11):1161-1173. doi: https://doi.org/10.1111/j.1464-5491.2004.01358.xEldor R, Raz I, Ben Yehuda A, Boulton AJ. New and experimental approaches to treatment of diabetic foot ulcers: a comprehensive review of emerging treatment strategies. Diabet Med. 2004;21(11):1161-1173. doi: https://doi.org/10.1111/j.1464-5491.2004.01358.xFalanga V. New treatment for diabetic foot ulcers (a) growth factors. In: Boulton AJ, Connor H, Cavanagh P, editors. The Foot in Diabetes. 3rd ed. Chichester: John Wiley &Sons; 2000. p. 169-178.Falanga V. New treatment for diabetic foot ulcers (a) growth factors. In: Boulton AJ, Connor H, Cavanagh P, editors. The Foot in Diabetes. 3rd ed. Chichester: John Wiley &Sons; 2000. p. 169-178.Papanas N, Maltezos E. Benefit-risk assessment of becaplermin in the treatment of diabetic foot ulcers. Drug Saf. 2010;33(6):455-461. doi: https://doi.org/10.2165/11534570-000000000-00000Papanas N, Maltezos E. Benefit-risk assessment of becaplermin in the treatment of diabetic foot ulcers. Drug Saf. 2010;33(6):455-461. doi: https://doi.org/10.2165/11534570-000000000-00000Профилактика и лечение заболеваний стопы при диабете. Руководство, документы и рекомендации. Полная русскоязычная версия. 2016. [International Consensus on the Diabetic Foot. Russian version. 2016. (In Russ.)]Профилактика и лечение заболеваний стопы при диабете. Руководство, документы и рекомендации. Полная русскоязычная версия. 2016. [International Consensus on the Diabetic Foot. Russian version. 2016. (In Russ.)]Marti-Carvajal AJ, Gluud C, Nicola S, et al. Growth factors for treating diabetic foot ulcers. Cochrane Database Syst Rev. 2015(10):CD008548. doi: https://doi.org/10.1002/14651858.CD008548.pub2Marti-Carvajal AJ, Gluud C, Nicola S, et al. Growth factors for treating diabetic foot ulcers. Cochrane Database Syst Rev. 2015(10):CD008548. doi: https://doi.org/10.1002/14651858.CD008548.pub2

The authors declare that there are no conflicts of interest present.